Japan News
-
US based C₂N Diagnostics expands Alzheimer’s diagnostics into Japan
Japan | News | 0 Comment | 30 Apr, 2024
C₂N Diagnostics, a specialty diagnostics company with a vision to bring Clarity Through Innovation, has announced a pa...Read more
-
Japan's Yokogawa helps to revolutionise Single-Cell Lipidomics
Japan | News | 0 Comment | 29 Apr, 2024
Japanese multinational company Yokogawa Electric Corporation’s latest single-cell analysis solution, the Single Ce...Read more
-
デュポンは STARLIMS を使用して 研究開発ラボでの試験を統合しました
Japan | News | 0 Comment | 11 Apr, 2024
200 年を超える歴史があるデュポンは、常に先頭に立って化学分野における革新的なイノ...Read more
-
Japanese Foundation for Cancer Research collaborates with Takeda Pharma
Japan | News | 0 Comment | 24 Apr, 2024
Japanese Foundation for Cancer Research (JFCR) and Takeda Pharmaceutical have signed a partnership agreement with the go...Read more
-
Takeda, Astellas and Sumitomo to establish JV for drug discovery programmes in Japan
Japan | News | 0 Comment | 23 Apr, 2024
Takeda Pharmaceutical, Astellas Pharma and Sumitomo Mitsui Banking Corporation (SMBC), in Japan, have signed a master ag...Read more
-
Japan | News | 0 Comment | 22 Apr, 2024
Japan-headquartered Shimadzu Corporation and Tohoku University have opened the Shimadzu × Tohoku University Supers...Read more
-
Eisai's antiepileptic drug Fycompa injection formulation launches in Japan
Japan | News | 0 Comment | 18 Apr, 2024
Eisai Co. has announced that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (pera...Read more
-
Taiwan approves Japan-based Shionogi's influenza drug for paediatric use
Japan | News | 0 Comment | 17 Apr, 2024
Japanese pharma behemoth Shionogi & Co. has announced that its group company Taiwan Shionogi has received approv...Read more
-
Nanoform partners with CBC to bring best-in-class nanomedicine technology to Japan
Japan | News | 0 Comment | 15 Apr, 2024
Nanoform Finland Plc has announced a strategic partnership whereby CBC Co. will utilise its extensive experience in the ...Read more
-
World Orphan Drug Alliance expands to Japan & South Korea
Japan | News | 0 Comment | 12 Apr, 2024
The World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to tre...Read more
-
Japan | News | 0 Comment | 10 Apr, 2024
Japan-headquartered Canon Medical Systems Corporation and Hiroshima University have begun clinical research, using a Can...Read more
-
French sales subsidiary of Japanese pharma firm Eisai divests rights of neurology drugs for € 56.5 M
Japan | News | 0 Comment | 09 Apr, 2024
Japan headquartered pharma company Eisai Co. has announced that its French sales subsidiary Eisai S.A.S. has entered int...Read more
-
Japanese firms Mitsui & Rohto Pharma buy Singapore-based consumer healthcare brand for ¥88 B
Japan | News | 0 Comment | 08 Apr, 2024
Japan-based Mitsui & Co., has decided to acquire shares in Eu Yan Sang International (EYS) jointly with Rohto Pharma...Read more
-
Japan-based Shimadzu acquires California X-ray Imaging Services
Japan | News | 0 Comment | 05 Apr, 2024
Japan headquartered Shimadzu Corporation has acquired all shares of California X-ray Imaging Services, Inc. (CIS) throug...Read more
-
Japan's NS Pharma & UK-based MiNA Therapeutics lay focus on rare diseases of Central Nervous System
Japan | News | 0 Comment | 04 Apr, 2024
NS Pharma, Inc. has announced that its parent company, Nippon Shinyaku Co., headquartered in Kyoto, Japan, has ente...Read more
-
Japan | News | 0 Comment | 03 Apr, 2024
AW Technologies and Asahi Kasei Medical, a core operating company of the Japanese technology company Asahi Kasei, have e...Read more
-
Eisai to divest rights for Merislon and Myonal in Japan to Kaken Pharma for ¥ 3.8 B
Japan | News | 0 Comment | 29 Mar, 2024
Eisai Co. has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon ...Read more
-
Japan | News | 0 Comment | 28 Mar, 2024
Nippon Shinyaku and Eli Lilly Japan K.K have entered into an alliance agreement in Japan for pirtobrutinib, which ...Read more
